BACKGROUND
After introduction of measles vaccine into routine immunization schedules of the 53 member states of the European Region (EUR) of the World Health Organization (WHO), there was a dramatic decrease in the rate of measles. In 2002, the European Region adopted a goal: elimination of measles and rubella by 2010 [1, 2] using the strategy outlined in Table 1 [3] . Activities are focused on reaching elimination through strengthening immunization systems to achieve high (R95%) coverage with 2 doses of measles vaccine and at least 1 dose of rubella vaccine through routine immunization services. In countries with large cohorts susceptible to measles virus, one-time catch-up supplementary immunization activities (SIAs) were conducted in wide-target age groups (up to 40 years in some countries). EUR countries generally rely on routine immunization rather than follow up SIAs to maintain high 2-dose coverage in young children. The strategy also includes advocacy efforts, such as European Immunization Week (EIW), to provide health care professionals with accurate and relevant information on measles disease and vaccine safety.
Monitoring progress towards achieving the goal of measles elimination relies on quality surveillance and accurate reporting of vaccine coverage. To assess progress, to identify remaining challenges, and to identify approaches to address these challenges, we reviewed data on measles epidemiology, vaccine coverage, and surveillance activities in the European Region during [2003] [2004] [2005] [2006] [2007] [2008] [2009] . (For the purpose of this report, the 53 Member States of the European Region were grouped into the following subregions: Western Europe (WE): Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, the Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, Turkey, and the United Kingdom; Central and Eastern Europe (CEE): Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, the Former Yugoslav Republic of Macedonia, Montenegro, Poland, Romania, Serbia, Slovakia, and Slovenia; and Newly Independent States (NIS) of former Soviet Union: Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Republic of Moldova, Russian Federation, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan.)
METHODS
Aggregate counts of measles cases, vaccine coverage, and vaccination schedules submitted annually to the WHO Regional Office for Europe using the WHO/the United Nations Children's Fund (UNICEF) Joint Reporting Form were reviewed for the period 1991-2009 [4, 5] . Since 2002, countries have been encouraged to report case-based data (eg, age, vaccination status, and laboratory confirmation status for individual measles cases) and data on measles outbreaks on a monthly basis. At national levels, different methods are used to collect information from local health authorities, including aggregate, case-based, and sentinel physician reporting. The European Regional Office uses a computerized information system for infectious diseases (CISID) [6] with monthly reporting of surveillance data by countries. Twenty-seven member states of the European Union and Croatia, Iceland, Norway, Switzerland, and Turkey report to the CISID through EUVAC.NET [7] . The EUR laboratory network for measles and rubella surveillance comprises 51 national laboratories, as of 2009, using standardized diagnostic methods and reagents, and 4 regional reference laboratories providing external quality assurance to the national laboratories and sequencing viruses. Laboratories report measles and rubella testing results and performance diagnostics online each month to the Regional Office and the Regional Office provides feedback to them on their performance using standardized indicators. A quality assessment program, which includes an annual accreditation review and proficiency testing, is in place. Coverage data during SIAs were reported by countries with independent evaluations in 6 countries (Armenia, Azerbaijan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan) that confirmed the high coverage achieved in these campaigns.
A review of feasibility of reaching the elimination goal by the 2010 target date for the entire region and for each country was conducted in 2009. The likelihood of measles elimination was assessed as ''feasible,'' ''probable,'' or ''unlikely'' on the basis of disease incidence, routine immunization coverage, quality of SIAs, surveillance performance, and overall progress made by each country.
RESULTS

Trends in Measles Incidence
The incidence of measles decreased from almost 400 cases per 1,000,000 population (304,214-342,031 cases) during 1991-1993 to 7. 4. Improving the availability of high-quality information for health professionals and the public on the benefits and risks associated with immunization against measles and rubella.
Bulgaria, which accounted for 30.9% (n 5 2249) of all reported cases in EUR in 2009. When Bulgaria was excluded, incidence in other CEE countries was 1.0 case per 1,000,000 population. The greatest progress was seen in low-income countries, which had incidence rate of 0.5 cases per 1,000,000 population in 2008 and no cases reported in 2009 ( Table 2 ). The rates among lower-middle income countries were higher than in the other income groups during 2004-2006 but have since decreased to low levels (ie, ,1 case per 1,000,000 population) of measles incidence. The 2009 outbreak in Bulgaria reversed the decrease in the incidence observed in upper-middle income countries. The highest rates during 2008-2009 were reported in upperincome countries ( Table 2 ).
The measles incidence was lowest for countries with R95% coverage for both measles-containing vaccine (MCV) 1 and MCV2, and highest for countries with ,95% coverage for both MCV1 and MCV2 (Table 2 ). However, during 2005-2006, the majority of cases were reported in CEE and NIS among older children and adults-age groups that were not targeted through current routine -38.1% of reported measles cases required hospitalization. In general, the proportion of hospitalized patients was higher in NIS and CEE, where patients with measles are routinely hospitalized; in other countries, patients with more severe cases are generally hospitalized. During 2003-2009, 52 measles-related deaths were reported from 16 countries. Nearly onehalf (47%) of the deaths for which age was reported occurred in persons aged R10 years, whereas 44% were reported among children aged ,5 years. Furthermore, 83% of the persons who died had received never been vaccinated (n 5 40) or received 1 dose (n 5 3) of a MCV. 
Providing a Second Measles Vaccination Opportunity Through SIAs
SIAs involving wide age range (up to 40 years) have been conducted throughout the region and are discussed in detail elsewhere [8, 9] . During 2003-2009, nationwide catch-up SIAs were conducted in Armenia, Azerbaijan, Croatia, Georgia, Ireland, Kazakhstan, Kyrgyzstan, Republic of Moldova, Russian Federation, Serbia, Tajikistan, Turkey, Turkmenistan, and Uzbekistan, achieving R94% coverage in all countries except Ireland (70.8% coverage), and Georgia (50.3%) and reaching .55 million persons. Combination vaccines containing both measles and rubella components were widely used, allowing rubella susceptibility to be addressed as well. Unfounded vaccine safety concerns affected 2 SIAs in 2008, leading to the suspension of the SIA in Ukraine and low (50.3%) coverage in the SIA in Georgia. Substantial decreases in measles incidence were observed in all countries after the SIAs. In 2009, the overall measles incidence in countries where SIAs were successfully implemented was at an all-time low, with Armenia, Kazakhstan, Kyrgyzstan, Republic of Moldova, Tajikistan, Turkmenistan, and Uzbekistan reporting no measles cases and Azerbaijan, Croatia, Russian Federation, Serbia, and Turkey having ,1 reported case per 1,000,000 population. 
Improving Available Vaccine Information Through EIW
To strengthen political commitment to immunization programs, mobilize communities, and provide high quality reliable information about vaccination, the annual EIW was established in 2005. The WHO European Regional Office facilitates member states' efforts to advocate for and strengthen awareness among political leaders, health care professionals, and the general population about measles and rubella elimination through the protection of children through immunization [11] . Participation in EIW has grown from 6 countries in 2005 to 36 countries in 2009. conducting catch-up immunization and increasing awareness of vaccine safety of health care professionals through training and workshops.
Feasibility of Measles Elimination by the 2010 Target Date
The likelihood of measles elimination by 2010 was assessed as ''feasible'' for 23 countries (ie, Albania, Andorra, Belarus, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Hungary, Iceland, Kyrgyzstan, Latvia, Lithuania, Luxembourg, Republic of Moldova, Monaco, Montenegro, Norway, Portugal, Russian Federation, Slovakia, Slovenia, Turkmenistan; the assessment was performed before the outbreak in Bulgaria); 7 countries were in western Europe, 11 were in CEE, and 5 were NIS), as ''probable'' for 20 countries (ie, Armenia, Azerbaijan, Belgium, Bosnia and Herzegovina, Cyprus, Denmark, Greece, Kazakhstan, Malta, the Netherlands, Poland, Romania, San Marino, Serbia, Spain, Sweden, Tajikistan, the Former Yugoslav Republic of Macedonia, Turkey, and Uzbekistan; 9 countries were in western Europe, 6 were in CEE, and 5 were NIS), and as ''unlikely'' for the remaining 10 countries (ie, Austria, France, Georgia, Germany, Ireland, Israel, Italy, Switzerland, UK the United Kingdom, and Ukraine; 8 were in western Europe, and 2 were NIS).
DISCUSSION
Evidence shows that it is technically feasible to eliminate measles from a geographic area [12] . Since adoption of the elimination goal in the WHO European Region, the number of reported measles cases has dramatically decreased. During 2007-2009, measles incidence in the region decreased to historically low levels of %10 cases per 1,000,000 population. The number of countries with no reported measles cases or low (,1 per 1,000,000 population) incidence has been increasing. The decrease in measles cases is a result of high immunization coverage with 2 doses of MCV and of implementation of SIAs targeting remaining susceptible age cohorts, which reached .55 million persons during [2003] [2004] [2005] [2006] [2007] [2008] [2009] . Surveillance for measles has also been strengthened by improving case investigation procedures and expanding case-based reporting, including laboratory testing. The establishment of the measles and rubella regional laboratory network, modeled on that for poliomyelitis, provides data for timely confirmation of cases and monitoring circulating measles virus genotypes.
Although there have been many achievements, challenges still exist in reaching the elimination goal, as evidenced by the ongoing measles outbreaks, which have led to unnecessary illness and death. Moreover, ongoing transmission in western Europe has been linked to multiple introductions of measles virus into other regions, including the Americas, which have eliminated indigenous measles [13, 14] .
The major challenge to achieving the regional measles elimination goal by 2010 is failure to vaccinate on time or the decision not to immunize. Although national measles immunization coverage estimates remain high, coverage at the subnational level and among high-risk and vulnerable populations in many countries has been revealed to be much lower than the recommended R95% or higher for 2 doses. Challenges to ensuring strong immunization services are present both in countries undergoing health care reform and in those with stable and well-funded primary health care systems. Resulting pockets of susceptible individuals can support disease transmission and cause outbreaks of measles, as was the case with the resurgence of measles cases in western Europe and CEE countries [7, 15, 16] .
Most outbreaks are in unimmunized populations (eg, hardto-reach, vulnerable populations and groups with vaccine safety concerns or with religious, philosophical, or cultural beliefs against immunization) in both high and low socioeconomic strata [7] . These countries must focus their efforts on immunizing these groups, especially the high-risk and vulnerable populations that have limited access to primary health care services for geographical, cultural, ethnic, or socioeconomic reasons. To minimize the risk of acquiring measles, particularly in countries with ongoing outbreaks, optimal timing of routine MCV administration should be ensured by implementing evidence-informed routine immunization schedules for measles. Countries should consider targeted supplementary immunization activities. Although these are not common practice in the western part of the region, catch-up vaccination campaigns among groups and individuals who have not been vaccinated can dramatically close the immunity gaps. With continued outbreaks and increasing incidence in some countries, it is not advisable to delay administration of MCV1 until after 12 months of age or to delay administration of MCV2 until after 6 years of age, as is the current policy in many countries of the region. In addition, every effort should be made to ensure that parents and health care workers adhere to existing immunization schedules and that children receive vaccines on time.
There is a need to restore the public's trust in immunization and to strengthen the understanding of the value of immunizations. In the near-absence of disease, immunization can lose priority, and perceived vaccine safety fears may outweigh concerns about risks of disease [7, 17] . As a result, there is a shift in public perception from the risk, implications, and severity of the disease to the vaccines safety issues. This has been exacerbated by misinformation about immunizations and the influence of antivaccination groups.
Communication initiatives should be developed by countries targeting the concerns of the nonimmunized or underimmunized people. Strategies for creating demand for immunization among identified populations need to be developed and implemented. The WHO European Regional Office will provide guidance on implementing behavioral models to address identified reasons for the failure to immunize. Countries need to employ a multisectoral approach with partners, including the use of civil society organizations to address their main challenges, including vaccine refusals. A focus on strengthening the knowledge of immunizations and vaccinology among health care professionals who are the trusted health advisers for many individuals will increase the opportunity for immunization. Where countries identify specific age cohorts susceptible to measles, additional immunization efforts, including wide-scale SIAs, will need to be considered to ensure they are immunized.
To monitor progress towards the elimination goal and document its achievement, national surveillance systems must be able to rapidly detect and confirm cases. High-quality case-based surveillance is critically important as the foundation for detection, laboratory diagnosis, and classification of all cases and contact tracing. Although surveillance systems for measles are functional in most countries, and although reporting to WHO on a monthly basis has been implemented, the completeness and timeliness of reporting measles cases are at times suboptimal. To further strengthen surveillance and to better monitor indicators of system performance, case-based surveillance must be used in all countries. Measles virus sequencing, a critical tool for monitoring circulating genotypes and documenting the interruption of indigenous transmission, has been widely implemented in the region. This practice needs to be sustained and further expanded. Implementation of recently published updated guidelines of surveillance for measles and rubella in the European Region, adapted for the final stages of measles and rubella elimination efforts in the region [18] , is expected to contribute substantially to further improvement of surveillance.
The regional strategy and tools for measles and rubella elimination are effective if implemented fully and appropriately, as evidenced by the progress made towards measles and rubella elimination in the region, with some member states (eg, Finland, Iceland, and Norway) [19] likely having sustained interruption of endemic transmission of one or both of the diseases. The regional elimination goals are attainable, albeit not by the present target date of 2010 ( Figure 5) . Recently, in September 2010, the European Regional Committee revised the target date for elimination to 2015 [20] . The European Region is at a point where measles rates are low, but at a time when increased political commitment, financial resources, and efforts are needed. With additional accelerated actions (Table 3) , countries will be able to interrupt indigenous transmission, and the region can achieve the elimination goal by 2015. It is urgent that countries renew their political commitment at all levels and ensure that societal support to the elimination goals is strengthened. In addition, countries must mobilize the required human and financial resources to reach the goal. The WHO European Regional Office will provide leadership and guidance on placing greater emphasis on leveraging global and regional resources and opportunities through existing partnerships and other sources of global and regional expertise. To achieve the rubella elimination goal, it must also be integrated with the measles immunization strategy and surveillance system.
The recent polio outbreak in the WHO European Region, which had been polio-free since 2002 [21] , is a sobering reminder how fragile the gains to date are; without sustained efforts, they can be lost quickly. Routine immunization programs are the cornerstone of these eradication and elimination goals, and without strong health systems, the goals will be in jeopardy. If the countries of the European Region are fully committed to eliminating measles, accelerated actions must be taken now to ensure that the gains made to date are sustained, so that the goal can be achieved.
